six hundred nineteen patients with metastatic breast cancer , treated with a combination of 5-fluorouracil , adriamycin , and cyclophosphamide , or close variations of this program , with or without immunotherapy were analyzed retrospectively to identify those host , tumor , or treatment characteristics that might be of prognostic importance in predicting response to chemotherapy and survival from onset of the 5-fluorouracil-adriamycin-cyclophosphamide treatments .
C0016360
fluorouracil
C0055160
fluorouracil